Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients with Relapsed Multiple Myeloma Treated with Thalidomide but Not for Those Treated with Bortezomib

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 123-130

  Smetana, Jan ^a   Berankova, Kristina ^a   Zaoralova, Romana ^a   Nemec, Pavel ^a   Greslikova, Henrieta ^a   Kupska, Renata ^a   Mikulasova, Aneta ^a   Frohlich, Jan ^a   Sevcikova, Sabina ^a   Zahradova, Lucie ^b   Krejci, Marta ^b   Sandecka, Viera ^b   Almasi, Martina ^a   Kaisarova, Petra ^a   Melicharova, Hana ^a   Adam, Zdenek ^b   Penka, Miroslav ^a   Jarkovsky, Jiri ^a   Jurczyszyn, Arthur ^c   Hajek, Roman ^a,b   Kuglik, Petr ^a   more..

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Bortezomib; Chromosomal aberrations; FISH; Multiple myeloma; Survival; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CHROMOSOME 1; CHROMOSOME ABERRATION; CHROMOSOME DELETION; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; INCIDENCE; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RELAPSE; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PYRAZINES; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME; TRISOMY;

EID: 84877341514     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.11.012     Document Type: Article

References (47)

1. P. Moreau, C. Hullin, F. Garban Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol Blood 107 2006 397 403 (Pubitemid 43053569)
2. B. Barlogie, V. Bolejack, M. Schell Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival Ann Hematol 90 2011 423 428
3. S.K. Kumar, H. Uno, S.J. Jacobus Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone Blood 118 2011 4359 4362
4. R. Fonseca, B. Barlogie, R. Bataille Genetics and cytogenetics of multiple myeloma: a workshop report Cancer Res 64 2004 1546 1558 (Pubitemid 38235629)
5. Y. Zhou, B. Barlogie, J.D. Shaughnessy Jr The molecular characterization and clinical management of multiple myeloma in the post-genome era Leukemia 23 2009 1941 1956
6. N.V. Smadja, C. Bastard, D. Brigaudeau Hypodiploidy is a major prognostic factor in multiple myeloma Blood 98 2001 2229 2238
7. R. Fonseca, E. Blood, M. Rue Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood 101 2003 4569 4575 (Pubitemid 36857829)
8. R. Fonseca, D. Harrington, M.M. Oken Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group Study Cancer Res 62 2002 715 720 (Pubitemid 34126946)
9. Kip1 and an aggressive clinical course in multiple myeloma Hematology 10 suppl 2005 117 126 (Pubitemid 41829514)
10. F. Zhan, S. Colla, X. Wu CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms Blood 109 2007 4995 5001 (Pubitemid 46827799)
11. P. Nemec, Z. Zemanova, H. Greslikova Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy Biol Blood Marrow Transplant 16 2010 548 554
12. F. Zhan, Y. Huang, S. Colla The molecular classification of multiple myeloma Blood 108 2006 2020 2202
13. H. Avet-Loiseau, M. Attal, P. Moreau Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe francophone du Myelome Blood 109 2007 3489 3495 (Pubitemid 46572539)
14. S. Singhal, J. Mehta, R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
15. M.A. Dimopoulos, K. Zervas, G. Kouvatseas Thalidomide and dexamethasone combination for refractory multiple myeloma Ann Oncol 12 2001 991 995 (Pubitemid 32725775)
16. B. Barlogie, M. Zangari, T. Spencer Thalidomide in the management of multiple myeloma Semin Hematol 38 2001 250 259 (Pubitemid 32717662)
17. B. Barlogie Thalidomide and CC-5013 in multiple myeloma: the university of Arkansas experience Semin Hematol 40 suppl 4 2003 33 38 (Pubitemid 37532258)
18. S.V. Rajkumar, P.G. Richardson, T. Hideshima Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 2005 630 639 (Pubitemid 46224241)
19. P.G. Richardson, B. Barlogie, J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617 (Pubitemid 36741588)
20. J.F. San Miguel, R. Schlag, N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 2008 906 917
21. S. Jagannath, B.G. Durie, J. Wolf Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 2005 776 783 (Pubitemid 40904528)
22. P.G. Richardson, A. Chanan-Khan, R.L. Schlossman Phase II trial of single agent bortezomib (Velcade) in patients with previously untreated multiple myeloma (MM) Blood 104 suppl 2004 100a
23. J.L. Harousseau, M. Attal, V. Coiteaux Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study J Clin Oncol 23 suppl 2005 598s
24. M.V. Mateos, J. Blade, J. Diaz Mediavilla A phase I/II national, multicenter, open-label study of bortezomib plus melphalan and prednisone (VMP) in elderly untreated multiple myeloma patients Blood 104 suppl 2004 943a
25. H. Avet-Loiseau, X. Leleu, M. Roussel Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) J Clin Oncol 28 2010 4630 4634
26. M.V. Mateos, N.C. Gutiérrez, M.L. Martín-Ramos Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance Blood 118 2011 4547 4553
27. S. Jagannath, P.G. Richardson, P. Sonneveld Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials Leukemia 21 2007 151 157 (Pubitemid 44921846)
28. V. Sagaster, H. Ludwig, H. Kaufmann Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion Leukemia 21 2007 164 168 (Pubitemid 44921848)
29. H. Chang, Y. Trieu, X. Qi Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains Leuk Res 35 2011 95 98
30. G.J. Ahmann, S.M. Jalal, A.L. Juneau A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies Cancer Genet Cytogenet 101 1998 7 11 (Pubitemid 28071352)
31. J. Cumova, L. Kovarova, A. Potacova Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting Int J Hematol 92 2010 314 319
32. F.M. Ross, H. Avet-Loiseau, J. Drach European Myeloma Network recommendations for FISH in myeloma Haematologica 92 2007 abstract 114
33. B.G. Durie, J.L. Harousseau, J.S. Miguel International uniform response criteria for multiple myeloma Leukemia 20 2006 1467 1473 (Pubitemid 44264086)
34. R. Fonseca, P.L. Bergsagel, J. Drach International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 23 2009 2210 2221
35. J.R. Sawyer, J.A. Waldron, S. Jagannath Cytogenetic findings in 200 patients with multiple myeloma Cancer Genet Cytogenet 82 1995 41 49
36. A.K. Stewart, R. Fonseca Prognostic and therapeutic significance of myeloma genetics and gene expression profiling J Clin Oncol 23 2005 6339 6344 (Pubitemid 46218844)
37. J.R. Sawyer, G. Tricot, S. Mattox Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin Blood 91 1998 1732 1741 (Pubitemid 28110339)
38. R. Fonseca, S.A. Van Wier, W.J. Chng Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma Leukemia 20 2006 2034 2040 (Pubitemid 44614894)
39. J.R. Sawyer The prognostic significance of cytogenetics and molecular profiling in multiple myeloma Cancer Genet 204 2011 3 12
40. P. Sonneveld, I.G. Schmidt-Wolf, B. van der Holt Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial J Clin Oncol 30 2012 2946 2955
41. H. Chang, Y. Trieu, X. Qi Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma Leuk Res 31 2007 779 782 (Pubitemid 46855891)
42. M.A. Dimopoulos, E. Kastritis, D. Christoulas Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies Leukemia 24 2010 1769 1778
43. P. Nemec, Z. Zemanova, P. Kuglik Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial Leuk Lymphoma 53 2012 920 927
44. M. Attal, J.L. Harousseau, S. Leyvraz Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 108 2006 3289 3294
45. I. Hanamura, J.P. Stewart, Y. Huang Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation Blood 108 2006 1724 1732 (Pubitemid 44316143)
46. D. Reece, Y. Trieu, H. Chang Treatment of relapsed and refractory multiple myeloma in patients with p53 deletion Blood 2008 abstract 1724
47. H. Greslikova, R. Zaoralova, H. Filkova Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation Neoplasma 57 2010 111 117